Factor Bioscience
- Biotech or pharma, therapeutic R&D
Factor Bioscience is developing advanced cell engineering therapies using its proprietary RNA-based gene-editing platform. Factor's pipeline includes autologous, allogeneic, iPSC-derived, and in-vivo CAR-T and myeloid/macrophage programs for oncology and immunology indications. Factor is planning to file a BLA for the first dual CAR-T targeting rrMM with extramedullary disease in Q1 2027 and is actively seeking to partner this and other programs.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}